Telix Pharmaceuticals Ltd cash flow statement

In fiscal 2025, Telix Pharmaceuticals Ltd's operations generated −$17.3m of cash; it spent $25.7m on capital projects, leaving free cash flow of −$43.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Telix Pharmaceuticals Ltd: cash flow statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	14	27	−17
Depreciation and amortisation	4	5	22
Stock-based pay	6	13	19
Capital spending	6	9	26
Free cash flow	8	18	−43
Free cash flow after stock pay	2	5	−62

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: TGTX vs TLX ASND vs TLX IONS vs TLX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Telix Pharmaceuticals Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Telix Pharmaceuticals Ltd.